NCT05764122View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 29, 2024

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions
Ischemic Stroke
Interventions
DRUG

BIIB131

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY